Immune checkpoint inhibitors: making immunotherapy a reality for the treatment of lung cancer.
Immune checkpoint inhibitors: making immunotherapy a reality for the treatment of lung cancer.
复制标题
DOI：
10.1158/2326-6066.cir-13-0078
复制
发表时间：
2013-08
影响因子：
10.1
通讯作者：
Pardoll DM
中科院分区：
文献类型：
--
作者：
Brahmer JR;Pardoll DM
尽管免疫疗法在实体恶性肿瘤中的成功有限，但两种人类癌症，黑色素瘤和肾癌，多年来对免疫靶向生物制剂的全身施用有反应，并显示出对某些治疗性疫苗的反应信号。这些发现支持了一个长期存在的观点，即黑色素瘤和肾癌具有独特的“免疫原性”，但几乎所有其他人类癌症都没有，因此不会对免疫调节产生反应。这一概念现在已经被阻断PD-1检查点的抗体治疗诱导的非小细胞肺癌的显著和持久反应所打破。因此，肺癌免疫疗法的成功为开发多种癌症类型的治疗方法提供了一个途径，这些癌症类型以前被认为是免疫疗法无法获得的。
Despite the limited success of immunotherapies in solid malignancy, two human cancers, melanoma and renal cancer, have, for many years, responded to systemic administration of immune-targeted biologics and showed signals of response to certain therapeutic vaccines. These findings underpinned a long-held perception that melanoma and renal cancer were uniquely "immunogenic" but that virtually all other human cancers were not and thus would not respond to immune modulation. That notion has now been shattered by the significant and durable responses in non–small cell lung cancer induced by therapeutic treatment with antibodies blocking the PD-1 checkpoint. The immunotherapy success in lung cancer thus provides a gateway to development of treatments for multiple cancer types that were previously believed not accessible to immune-based therapies.